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induced release of calcium from the sarcoplasmic
reticulum.1
Heart failure is a common end result of a variety of
cardiac diseases. As this condition develops, the density
and affinity of BARs are both known to decrease as a
result of an increase in BAR kinase activity, and this is
followed by a deterioration in cardiac function.2,3
Administration of an adrenergic beta-blocking agent or
an angiotensin-converting enzyme inhibitor is normally
used for such situations.4,5 However, the improvement in
cardiac function achieved by these therapies is limited. 
Gene therapy for human beings has widespread
potential applications in clinical medicine.6 Various
techniques involving gene transfection into the heart
have been tested experimentally.7 For instance, Milano
and associates2 created transgenic mice overexpressing
beta 2–adrenergic receptor (B2AR). They reported that
T he beta-adrenergic receptor (BAR) system plays amajor role in cardiac contraction.1 Stimulation of
the BAR itself leads to activation of adenylyl cyclase
and the subsequent production of cyclic adenosine-
3´5´-monophosphate.1 The intracellular calcium level is
increased by an opening of the slow calcium channel,
and the level is then markedly increased by calcium-
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cardiac function was markedly enhanced, indicating
the potential of gene transfer for enhancing cardiac
function. However, this transgenic technique causes
chronic changes in the essential characteristics of the
model, and the technique is not suitable as a therapeu-
tic approach for human beings. 
Recently, we reported that a hemagglutinating virus
of Japan (HVJ) liposome method could be used as a
novel in vivo technique for the transfer of genes into the
whole heart with a high efficacy.8 If the BAR of the
heart could be increased by gene transfection by intra-
coronary infusion of a plasmid carrying the B2AR
complementary DNA, and cardiac function thus
enhanced, it might prove possible to use this maneuver
as an approach to enhance cardiac function. 
In this study, we transfected B2AR cDNA into the
normal rat hearts and examined whether such gene was
overexpressed in the whole heart and gene transfection
was effective in improving the cardiac response to iso-
proterenol. 
Methods 
Animals. Sprague-Dawley rats weighing 200 to 250 g were
used in this study. The rats were treated humanely according
to the “Principles of Laboratory Animal Care” formulated by
the National Society for Medical Research and the “Guide for
the Care and Use of Laboratory Animals” prepared by the
Institute of Laboratory Animal Resources and published by
the National Institutes of Health (NIH Publication No. 86-23,
revised 1985). 
DNA construct. Human B2AR cDNA was supplied by Dr
R. J. Lefkowitz (Department of Medicine, Duke University,
Durham, NC).9 It was cloned at the XhoI/HindIII site of
pcDNA3.1(–), which has a cytomegalovirus promoter
(Invitrogen Corporation, San Diego, Calif). As a control, a
DNA construct of pcDNA3.1(–) that does not include B2AR
cDNA was used. 
Transfection using an HVJ-liposome method. The
preparation of the HVJ liposome has been described else-
where.10,11 In brief, 10 mg of lipid mixture (phosphatidylser-
ine, phosphatidylcholine, and cholesterol) was deposited on
the wall of a flask by removing tetrahydrofuran in a rotary
evaporator. The dried lipid was hydrated in 200 m L of bal-
anced salt solution (NaCl, 137.0 mmol/L; KCl, 5.4 mmol/L;
Tris-HCl, 10.0 mmol/L; pH 7.6) containing a DNA (50 m g)-
HMG1 (high mobility group 1 nuclear protein, 64 m g) com-
plex. A liposome-DNA-HMG1 complex suspension was pre-
pared by spinning in a vortex, sonicating, and shaking to form
liposomes. The liposome suspension was incubated with
30,000 hemagglutinating units of HVJ (inactivated by ultra-
violet irradiation), first at 4°C and then at 37°C. Finally, 4 mL
of the sucrose gradient layer containing the HVJ-liposome-
DNA complex was collected for use.
Transfection of the B2AR.8 The Sprague-Dawley rat was
anesthetized with sodium pentobarbital (0.5 mL/kg, intraperi-
toneally). The heart was arrested by infusion of cardioplegic
solution, which contained the following (in millimoles per
liter): NaCl, 110.0; NaHCO3, 10.0; KCl, 16.0; MgCl2, 16.0;
CaCl2, 1.2; and lidocaine, 1.0. Both caval veins were ligated
and transected. After branches of the aortic arch had also
been ligated, the descending aorta was transected. Then the
pulmonary arteries and veins were ligated and the heart was
removed. Approximately 0.7 mL of the HVJ-liposome-DNA
complex (including 50 m g of B2AR cDNA) was infused via
the aorta into the resected heart (“coronary perfusion”). The
heart was incubated on ice for 10 minutes to give sufficient
time for gene transfection into the cardiomyocytes.8 Then
transfected heart was transplanted into the abdomen of anoth-
er Sprague-Dawley rat of the same strain, with the recipient
rat under sodium pentobarbital anesthesia (0.5 mL/kg,
intraperitoneally). The transplantation was performed by
anastomosing the descending aorta to the abdominal aorta
and the pulmonary artery to the inferior caval vein in an end-
to-side fashion (a modification of the Ono and Lindsey tech-
nique12). The ischemic time was 40 ± 3 minutes. The trans-
planted hearts were resuscitated to spontaneous, continuous
beating after restoration of coronary blood flow. The hearts
transfected with the plasmid including the construct of B2AR
DNA are referred to as the transfected group (n = 25) and the
hearts transfected with the plasmid not including B2AR DNA
are designated the control group (n = 25). Four days after the
transfection, 5 hearts in each group were used for immuno-
histochemical labeling and 10 hearts for the ligand binding
assay; the cardiac function of the remaining 10 hearts in each
group was analyzed by means of a Langendorff system. 
Immunohistochemical labeling. Four days after transfec-
tion, 5 hearts from each group were removed and quickly
frozen in embedding medium (optimum cutting temperature
compound; Miles Inc, Diagnostics Division, Elkhart, Ind)
using liquid nitrogen. Then, the frozen sections were cut at 7
m m and rinsed 3 times for 3 minutes each time in phosphate-
buffered saline solution (PBS) and for 3 minutes in PBS with
0.05% Triton X-100 (Triton-PBS; Union Carbide Corp,
Danbury, Conn). They were then blocked with serum diluent
(10% goat serum in PBS with 0.1% bovine serum albumin
and 0.1% sodium azide). Next, the sections were rinsed for
15 minutes in Triton-PBS before overnight incubation at 4°C
with a primary rabbit antihuman BAR antiserum13 (1:3000
dilution in serum diluent). They were then washed 4 times for
10 minutes each time in Triton-PBS at room temperature and
incubated for 1 hour in fluorescein isothiocyanate–conjugat-
ed goat antirabbit immunoglobulin G (1:500 dilution in
serum diluent). After five 3-minute rinses in PBS, the sec-
tions were mounted with sodium iodide (25 mg/L) in 1:1
glycerol solution. 
Ligand binding assay. Four days after transfection, hearts
were removed from the recipient rats (10 from each group)
and quickly frozen with liquid nitrogen. Then, to isolate the
sarcolemma of the myocytes, the ventricles of the transfected
hearts were placed in ice-cold lysis homogenization buffer
(sucrose [0.25 mol/L] containing Tris-HCl [5 mmol/L] and
MgCl2 [l mmol/L], pH 7.4) and homogenized using a
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Polytron homogenizer (Nihon Seimitsu-Kogyo Co, Japan) 3
times for 15 seconds each time at a power setting of 6. After
an initial 800g centrifugation for 10 minutes, the supernatant
was filtered through a single layer of cheesecloth and cen-
trifuged at 30,000g for 30 minutes. The pellets were sus-
pended in a 5 mmol/L concentration of Tris-HCl buffer (Tris-
HCl, 50 mmol/L; MgCl2, 10 mmol/L; pH 7.4) and
recentrifuged at 30,000g for 30 minutes. Some of the resul-
tant pellets were resuspended in another buffer (Tris-HCl, 10
mmol/L; ethyleneglycoltetraacetic acid, 1 mmol/L; pH 7.4).
The assay buffer was Tris-HCl (20 mmol/L), NaCl (150
mmol/L), and ascorbic acid (1 mmol/L), pH 7.4, at room tem-
perature (Tris-NaCl buffer). For measurement of BAR densi-
ty, duplicate tubes were prepared containing 6 increasing
concentrations of [125I]-cyanopindolol (from 5.0 · 10–12
mol/L to 1.5 · 10–10 mol/L) with or without 10–6 mol/L (–)-
propranolol, giving a total volume of 150 m L. The assay was
begun by adding 300 µL of membrane preparation, and incu-
bation then proceeded for 60 minutes at 37°C. This method
allowed for complete equilibration of the receptor with the
radioligand. Bound and free ligands were separated by the
addition of 5 mL Tris-HCl buffer (at room temperature), rapid
filtration through Whatman GF/F filters (Whatman, Inc,
Clifton, NJ), and immediate washing with an additional 15
mL of the same buffer. Filters were counted at 70% efficien-
cy in a gamma counter (model MINAXI-gamma, Pachard Ins
Co, Meriden, Conn). The dose of membrane protein was
determined according to Bradford’s method.14
Measurement of cardiac function in the transfected rat
heart. Cardiac function was measured by a person who did
not know whether the heart was in the transfected group or in
the control group. Four days after transfection, recipient rats
(10 from each group) were anesthetized with sodium pento-
barbital (0.5 mL/kg, intraperitoneally) and killed after an
intravenous infusion of heparin (1000 U/kg). The hearts were
removed and immersed in cold (4°C) buffer. Each heart was
then mounted on the aortic cannula (2.5 mm outside diame-
ter) of the perfusion apparatus. The coronary arteries were
perfused according to the Langendorff technique at a perfu-
sion pressure of 100 cm H2O for both groups. The Krebs-
Henseleit solution contained the following (in millimoles per
liter): NaCl, 118.5; NaHCO3, 25.0; KCl, 4.8; MgSO4, 1.2;
CaCl2, 1.25; and glucose, 11.0. The buffer was filtered (5-µm
pore size) before use and was continuously gassed with 95%
oxygen and 5% carbon dioxide to obtain pH 7.4 at 37°C.
Each heart was housed in a controlled heart chamber main-
tained at 37°C. During a 10-minute washout period after can-
nulation, an intraventricular balloon (8 mm in diameter) was
inserted into the left ventricle through the mitral valve. The
balloon was filled with fluid and attached to a pressure trans-
ducer through a fluid-filled tube. The volume of the balloon
was adjusted by means of a watertight microsyringe attached
to a side arm of the transducer. Before infusion of isopro-
terenol, heart rate, developed pressure, and maximal and min-
imal derivatives of the left ventricle (max and min dp/dt)
were measured at a constant left ventricular end-diastolic
pressure (set at 10 cm H2O for both groups). About 45 to 60
seconds after each infusion of isoproterenol (4 · 10–12 g, 2.5
· 10–10 g, 4 · 10–8 g, 2.5 · 10–6 g, or 1 · 10–5 g), maximum
values of heart rate, developed pressure, and max and min
Fig 1. Immunohistochemical labeling for human B2AR showing extensive overexpression of B2AR in the sar-
colemma of the cardiomyocytes of the transfected group. 
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dp/dt were also measured. The various concentrations of iso-
proterenol were applied in an ascending order.
Statistical analysis. All values are expressed as mean ±
standard deviation. Differences in receptor density were
assessed by means of a Mann-Whitney test. Differences in
cardiac function data were assessed with the use of a 2-way
repeated-measures analysis of variance. If a significant F
ratio was obtained, further analysis was carried out with
Duncan’s post hoc test. All analysis was performed with
SPSS statistical software (SPSS, Inc, Chicago, Ill). Differ-
ences between groups were considered significant at the P <
.05 level.
Results 
Mortality after gene transfection. There were no
technical failures and no operative deaths in the 25 con-
secutive trials in each group. 
Immunohistochemical labeling. No substantial
changes in histologic appearance occurred. Extensive
overexpression of B2AR in the sarcolemma of the car-
diomyocytes, in which B2AR are located, was well
labeled in the transfected group; by contrast, no part of
the heart was labeled in the control group (Fig 1). The
cytoplasm of the cardiomyocytes was not labeled in
either group. 
Ligand binding assay. The values for BAR density
in the hearts of the transfected and control groups were
134 ± 42 fmol/mg protein and 33 ± 4 fmol/mg protein,
respectively (P = .0001) (Fig 2).
Evaluation of cardiac function. The heart rates
obtained under basal conditions in the transfected and
control groups were 373 ± 60 beats/min and 347 ± 31
beats/min, respectively. In the transfected group, heart
rate was maximally elevated to 418 ± 36 beats/min
after infusion of 2.5 · 10–6 g of isoproterenol, and in
the control group it was maximally elevated to 438 ±
27 beats/min after infusion of 2.5 · 10–6 g of isopro-
terenol. Heart rate before and after infusion of each
dose of isoproterenol did not differ between the trans-
fected and control groups. 
Developed pressure under basal conditions was 74 ±
3 mm Hg in the transfected group and 76 ± 3 mm Hg
in the control group. In the transfected group, devel-
oped pressure was maximally elevated to 200 ± 12 mm
Hg after infusion of 2.5 · 10–6 g of isoproterenol,
Fig 2. Ligand binding assay for measurement of BAR densi-
ty showing significant increase of the density in the hearts of
the transfected group (P = .0001).
Fig 3. Cardiac response to isoproterenol (ISP). Top and mid-
dle, Changes of developed pressure (DP) and maximal deriv-
ative of the left ventricle (max dp/dt) showing the significant
increase in these values in the transfected group after each
infusion of isoproterenol of 4.0 · 10–12 g or more than those
in the control group (*P = .0001, **P = .0008, ***P = .0007).
Bottom, Changes of minimal derivative of the left ventricle
(min dp/dt) showing the significant decrease of the values in
the transfected group compared with that in the control group
after each infusion of isoproterenol of 4.0 · 10–12 g or more
(*P = .0001, ***P = .0007).
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whereas in the control group it was maximally elevated
to 174 ± 6 mm Hg after infusion of 2.5 · 10–6 g. Under
basal conditions, developed pressure did not differ
between the 2 groups, but the developed pressure in the
transfected group was significantly higher than that in
the control group after each infusion of isoproterenol of
4.0 · 10–12 g or more (P = .0001 or .0008) (Fig 3; top). 
Max dp/dt under basal conditions was 1184 ± 187
mm Hg/sec in the transfected group and 1230 ± 87 mm
Hg/sec in the control group. Max dp/dt was maximally
elevated to 4110 ± 130 mm Hg/sec after infusion of 4
· 10–8 g of isoproterenol in the transfected group and to
3491 ± 255 mm Hg/sec after infusion of 2.5 · 10–6 g of
isoproterenol in the control group. Under basal condi-
tions, max dp/dt did not differ between the 2 groups;
however, max dp/dt was significantly greater in the
transfected group than in the control group after each
infusion of isoproterenol of 4.0 · 10–12 g or more (P =
.0001 or .007) (Fig 3; middle). 
Min dp/dt under basal conditions was –743 ± 121
mm Hg/sec in the transfected group and –741 ± 75 mm
Hg/sec in the control group. Min dp/dt in the transfect-
ed group decreased to a minimum of –3040 ± 267 mm
Hg/sec after 4 · 10–8 g of isoproterenol and in the con-
trol group to –2528 ± 131 mm Hg/sec after 4 · 10–8 g
of isoproterenol. Min dp/dt did not differ between the 2
groups; however, min dp/dt was significantly lower in
the transfected group than in the control group after
each infusion of isoproterenol of 4.0 · 10 –12 g or more
(P = .001 or .0001) (Fig 3; bottom). 
Discussion
In this study, we have shown by gene transfection
using an HVJ-liposome method that the B2AR can be
successfully overexpressed in the normal rat heart and
that, as a result, an apparent enhancement in the cardiac
functional response was demonstrated in these trans-
fected rats.
Gene transfection into the heart has been proposed as
a new method of treatment for the failing heart or
myocardial damage. A number of trials have been
reported using such methods as intravenous infection,15
direct infection,16 or intracoronary infusion of a naked
plasmid.17 However, we have yet to see established a
method of gene transfection for the entire heart that is
satisfactory in the sense that it leads to overexpression
of a protein and modification of myocardial character-
istics with high efficiency. Recently, Sawa and associ-
ates8 reported an efficient in vivo gene transfection
method to the entire rat heart using the intracoronary
infusion of HVJ liposomes. Fluorescein isothiocyanate
and beta-galactosidase can be overexpressed in the
whole rat heart. Suzuki and coworkers18 also reported
that ischemia-reperfusion injury was attenuated when
heat shock protein 70 was overexpressed by this
method. In this method, 10 minutes of incubation (0°C)
is required to transform the vector including cDNA,
and more than 4 days is also required to express the
protein induced by the transfected cDNA.10,11
The BAR system has a major role in cardiac contrac-
tion.3 BAR itself mediates effects through activation of
adenylyl cyclase to produce cyclic adenosine-3´5´-
monophosphate, which increases intracellular concen-
tration of calcium and causes excitation-contraction
coupling.3 In the failing heart, density and affinity of
the receptor decrease and activity of BAR kinase
increases. These changes in the BAR system exacer-
bate cardiac dysfunction.1
Milano and associates2 created transgenic mice over-
expressing human B2AR and found that they displayed
marked improvements in left ventricular function.
Although the transgenic technique is a novel and useful
method for the evaluation of the effects of the super-
overexpression of specific genes, it has no value as a
therapeutic approach for human beings with cardiac
disease. An alternative therapeutic approach might be
an effective in vivo gene transfer method, one require-
ment being that the method chosen must be safe to use
in a patient with a failing heart. Since the HVJ-lipo-
some method used in this study requires 10 minutes of
incubation on ice for the HVJ-liposome-DNA complex
to adhere to the cardiomyocytes so that the DNA can be
transfected into the myocytes,10,11 approximately 10
minutes of cardiac arrest is needed to apply this tech-
nique to clinical settings. In fact, in vivo transfection of
the B2AR gene into the heart by intracoronary perfu-
sion should be possible in human beings as a surgical
technique during cardiac arrest under cardiopulmonary
bypass or as a catheter intervention technique during
cardiac arrest under a percutaneous cardiopulmonary
support system.8
The ability of our maneuver to enhance cardiac func-
tion could be questioned because there was no differ-
ence in cardiac function under basal conditions
between the transfected and control groups in this
study. However, we have an optimistic view of these
results: the intracellular calcium level, which is very
important in excitation-contraction coupling in car-
diomyocytes, is determined by the extracellular calci-
um level and the opening of the slow calcium channel.
As there was no beta-adrenergic agonist to induce
opening of the slow calcium channel under basal con-
ditions in our Langendorff perfusion system, it is not
surprising that cardiac function did not differ between
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the transfected and control groups in the absence of iso-
proterenol. The lack of increase in baseline condition in
the transfected group may also be related to desensiti-
zation or internalization of the receptor. Although fur-
ther study in larger animals will be needed to elucidate
this point, we would anticipate differences in cardiac
function under basal conditions in the intact animal. 
In summary, B2AR was able to be overexpressed
approximately 4 times in the whole rat hearts by gene
transfection using an HVJ-liposome method. The trans-
fected hearts demonstrated marked enhancements in
cardiac response after infusion of isoproterenol, sug-
gesting that this procedure may have a place in the
treatment of the failing heart and, in particular, may
provide us with a novel cardiac surgical procedure. 
We are grateful to Dr Robert J. Lefkowitz, James B. Duke
Professor of Medicine, Duke University Medical Center,
Durham, North Carolina, for his giving us the cDNA of
human beta 2 adrenergic receptor and for technical collabo-
ration and thoughtful advice. 
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